interaction with healthcare professionals who made clear their need for
this important information.
-- Dr. Lechleiter's email was nothing more than a call to action to ensure
Lilly's development organization placed a high priority on conducting
clinical trials to address these important medical questions. His
specific reference to "the opportunity to expand our work with
Zyprexa(R) (olanzapine)" referred directly to clinical development
already underway, not promotional activity. This email indicates his
support for continued company investment and focus in gathering this
critical information (such as data on safety, efficacy and dosing in
these special populations) to ensure it was not only submitted to
regulatory bodies, but also accessible so that doctors and caregivers
could make informed treatment decisions.
-- Of note, since this 2003 email, Lilly has since completed studies and
presented their findings at major peer-review venues such as medical
meetings, included these data in our medicines' product label (in the
safety information section) as well as submitted these data to the US
Food and Drug Administration for approval consideration.
-- As stated on many occasions, Lilly is committed to the highest ethical
standards and to promoting our medications only for approved uses. This
steadfast commitment begins at the top of our organization -- and
remains an utmost priority of both our current and incoming chief
executive officer -- and is carried throughout the company. Although
we realize the above point does not make for exciting news
copy, it is information that anyone who read the Times coverage should
Zyprexa is indicated in the United States for the short- and long-te
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved